Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCT for Primary Immunodeficiencies Using Fludarabine, TBI, and Alemtuzumab
NCT00553098Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2006
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in primary immunodeficiency disorder (PID), hemophagocytic lymphohistiocytosis (HLH), Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), DiGeorge syndrome (DGS), Inherited disorder, sponsored by Fred Hutchinson Cancer Center. Started Jun 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
primary immunodeficiency disorder (PID)hemophagocytic lymphohistiocytosis (HLH)Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)DiGeorge syndrome (DGS)Inherited disorder
Beyond the preview
Go deeper on NCT00553098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553098.